NASDAQ:SABS
SAB Biotherapeutics, Inc.
- Stock
Last Close
2.76
26/07 20:00
Market Cap
29.53M
Beta: 1.26
Volume Today
2.99K
Avg: 1.39M
PE Ratio
−10.36
PFCF: 7.38
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | ||||||
average payables | 4.78M - | 5.92M 23.95% | 4.07M 31.28% | 2.31M 43.16% | ||
average receivables | 11.69M - | 14.29M 22.20% | 6.78M 52.53% | 2.78M 59.04% | ||
book value per share | -0.05 - | 0.90 1,791.90% | 1.41 57.15% | 0.71 49.39% | 10.38 1,354.31% | |
capex per share | -0.01 - | -0.29 1,991.46% | -0.40 36.69% | -0.25 37.19% | -0.04 85.80% | |
capex to depreciation | -1.88 - | -23.23 1,133.89% | -6.62 71.51% | -6.62 0% | -0.05 99.20% | |
capex to operating cash flow | 0.07 - | -1.27 2,026.24% | -2.91 128.80% | -2.91 0% | 0.01 100.27% | |
capex to revenue | -0.18 - | -0.23 30.32% | -0.18 22.01% | -0.46 154.67% | -0.09 80.77% | |
cash per share | 0.15 - | 0.29 98.71% | 1.21 318.74% | 0.35 71.54% | 10.24 2,863.41% | |
days of inventory on hand | ||||||
days payables outstanding | 92.19 - | |||||
days sales outstanding | 298.92 - | 135.92 54.53% | 48.03 64.66% | 84.85 76.65% | ||
debt to assets | 0.42 - | 0.14 66.12% | 0.08 40.88% | 0.12 37.07% | 0.07 39.58% | |
debt to equity | -3.31 - | 0.21 106.29% | 0.17 16.02% | 0.19 9.12% | 0.10 46.00% | |
dividend yield | ||||||
earnings yield | -0.02 - | 0.05 313.62% | -0.08 279.20% | -0.73 793.41% | -1.11 52.17% | |
enterprise value | 442.56M - | 436.78M 1.31% | 187.06M 57.17% | 16.56M 91.15% | -12.67M 176.53% | |
enterprise value over ebitda | -53.75 - | 20.67 138.45% | -15.97 177.29% | -0.61 96.18% | 0.37 160.54% | |
ev to operating cash flow | -48.03 - | 43.66 190.90% | 49.77 14.00% | 4.41 91.15% | 0.50 88.55% | |
ev to sales | 128.58 - | 7.91 93.85% | 3.07 61.14% | 0.69 77.46% | -5.66 917.06% | |
free cash flow per share | -0.23 - | -0.06 72.24% | -0.26 319.00% | -0.17 37.19% | -4.59 2,677.51% | |
free cash flow yield | -0.02 - | -0.01 72.24% | -0.03 444.54% | -0.28 731.61% | -0.67 138.15% | |
graham net net | -0.27 - | 0.24 188.68% | -0.06 124.28% | -0.01 75.24% | 5.42 37,397.00% | |
graham number | 0.51 - | 3.06 501.19% | 4.50 47.21% | 2.63 41.56% | 42.24 1,506.57% | |
income quality | 1.03 - | 0.50 51.50% | -0.22 144.08% | -0.22 0% | 0.60 371.56% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -20.24 - | 43.82 316.46% | -45.48 203.80% | -95.89 110.81% | 120.77 225.95% | |
interest debt per share | 0.19 - | 0.20 6.56% | 0.26 30.22% | 0.14 44.40% | 1.01 607.49% | |
inventory turnover | ||||||
invested capital | -3.31 - | 0.21 106.29% | 0.17 16.02% | 0.19 9.12% | 0.10 46.00% | |
market cap | 441.27M - | 441.27M 0% | 213.52M 51.61% | 25.68M 87.98% | 37.99M 47.95% | |
net current asset value | -11.02M - | 16.92M 253.58% | 7.60M 55.09% | 2.25M 70.39% | 32.27M 1,333.58% | |
net debt to ebitda | -0.16 - | -0.21 35.27% | 2.26 1,165.00% | 0.34 85.14% | 1.48 339.53% | |
net income per share | -0.22 - | 0.46 313.62% | -0.64 237.89% | -0.43 32.52% | -7.64 1,674.77% | |
operating cash flow per share | -0.21 - | 0.23 208.58% | 0.14 40.26% | 0.09 37.19% | -4.55 5,368.26% | |
payables turnover | 3.96 - | |||||
receivables turnover | 1.22 - | 2.69 119.93% | 7.60 182.98% | 4.30 43.39% | ||
research and ddevelopement to revenue | 2.33 - | 0.51 78.32% | 0.94 85.92% | 1.52 62.28% | 7.38 383.88% | |
return on tangible assets | -0.52 - | 0.36 168.03% | -0.22 161.77% | -0.37 67.50% | -0.50 36.54% | |
revenue per share | 0.08 - | 1.27 1,504.91% | 2.23 75.25% | 0.55 75.34% | 0.41 26.17% | |
roe | 4.08 - | 0.52 87.37% | -0.45 187.74% | -0.60 33.35% | -0.74 22.04% | |
roic | -0.79 - | 0.37 146.65% | -0.26 171.20% | -0.70 165.67% | -0.57 18.67% | |
sales general and administrative to revenue | 1.19 - | 0.12 89.70% | 0.28 128.92% | 0.69 144.20% | 10.63 1,450.90% | |
shareholders equity per share | -0.05 - | 0.90 1,791.90% | 1.41 57.15% | 0.71 49.39% | 10.38 1,354.31% | |
stock based compensation to revenue | 0.11 - | 0.02 78.27% | 0.04 62.13% | 0.10 154.67% | 1.08 1,017.92% | |
tangible asset value | -2.31M - | 39.01M 1,791.90% | 38.55M 1.17% | 31.06M 19.43% | 57.30M 84.49% | |
tangible book value per share | -0.05 - | 0.90 1,791.90% | 1.41 57.15% | 0.71 49.39% | 10.38 1,354.31% | |
working capital | 4.67M - | 23.39M 400.85% | 23.74M 1.47% | 7.10M 70.07% | 48.09M 576.98% |
All numbers in USD (except ratios and percentages)